WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 06/01/23

2023-06-01 05:41:58 ET In response to global clients' increasing demand for contract manufacturing services, WuXi Biologics ( OTCPK:WXXWY ) notifies that it would boost production for drug substance and drug product in Germany. The investment promotes the creation ...

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations PR Newswire DUNDALK, Ireland , May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO)...

2023-05-08 14:56:19 ET Summary WuXi Biologics (Cayman) Inc.'s short-term and mid-term financial guidance suggests that the company's revenue and earnings growth rates will be slower than what they were in recent years. Potential financing difficulties for the company's customers a...

2023-05-04 05:21:00 ET Summary Baron Emerging Markets Fund gained 2.68% (Institutional Shares) during the first quarter of 2023, while its principal benchmark Index, the MSCI EM Index, returned 3.96%. The Fund may invest in companies of any market capitalization, and we have gener...

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability PR Newswire The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with 2022. The Company mak...

2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease PR Newswire WUXI, China , March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contr...

2023-03-22 09:00:04 ET Wuxi Biologics ADR press release ( OTCPK:WXXWY ): FY Non-GAAP EPS of RMB1.13. Revenue of RMB15.27B (+48.4% Y/Y). For further details see: Wuxi Biologics ADR Non-GAAP EPS of RMB1.13, revenue of RMB15.27B

Summary WuXi Biologics revenue growth slowed sharply to 48.4% last year, but it got a jumpstart with its signing of a major new order last month. The company's major shareholder recently sold 56 million shares, the latest in a steady series of such sales since its listing in 2017. I...

Summary WuXi Biologics outlicensed global rights for up to four pre-clinical bi- and multi-specific TCE antibodies to GSK in a $1.5 billion agreement. ArriVent Biopharma of Philadelphia is raising another $145 million to bring drugs from China and other emerging biotech hubs to the US m...